Fresh analysis suggests that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end conventional lifestyle plans.
Research printed in a prominent health publication points out that while obese individuals can lose substantial amounts of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these treatments must be aware of the potential of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
Such speed of regain implies a return to original mass in about one and a half years.
Comparing Approaches
The research, which examined 37 of studies involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
The team note that individuals who shed pounds through lifestyle changes alone typically see a less rapid creep back—approximately 100 grams monthly—after stopping.
Explaining the Rapid Regain
Experts believe the mode of action of the drugs accounts for the amplified rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone concentrations several times higher than normal could lead to the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making binge eating much more probable."
A Chronic Issue?
The NHS advise the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts say that, considering the significant potential of relapse, the treatment should be considered long-term.
This opinion is supported by drug manufacturers, who say that the results "underscore the long-term character of obesity," similar to managing diseases like hypertension.
User Accounts
Users who have come off the medication report a sudden return of cravings.
"It felt as if something flipping and you become starving," described one woman.
The struggle is worsened if patients have not established permanent lifestyle or habit modifications during therapy.
Significant Interest
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is greater among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent fix and lasting health benefits likely depends on integrated lifestyle management.
